SCHEMBL4833937

SCHEMBL4833937

NC1=c2ccsc2=NCN1c1ccc(NC(=O)c2cc(F)ccc2F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.43
▸ RAB9A P51151 5/20 0.43
▸ MAPT P10636 5/20 0.43
▸ TP53 P04637 5/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ GRM5 P41594 2/20 0.38
▸ LMNA P02545 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ POLB P06746 2/20 0.36
▸ FADS1 O60427 1/20 0.36
▸ BRAF P15056 1/20 0.36
▸ AVPR2 P30518 1/20 0.36
▸ TSHR P16473 1/20 0.35
▸ WNT1 P04628 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833807 0.89 RET (0.43) MAPTTP53LMNA
SCHEMBL4826956 0.83 JAK2 (0.43) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL4835896 0.82 ELOVL1 (0.42) NPC1RAB9AMAPTF10
SCHEMBL4828766 0.81 RAB9A (0.47) NPC1RAB9AMAPTSMN1; SMN2TDP1
SCHEMBL4835290 0.79 RAB9A (0.49) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL4826276 0.78 RAB9A (0.54) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL4833596 0.77 MAPK8 (0.45) NPC1RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL4828956 0.75 CSF1R (0.41) MAPTLMNA
SCHEMBL4826345 0.75 NPC1 (0.37) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4831024 0.75 TRPV1 (0.50) NPC1MAPTSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK NPC1 4117/4885RAB9A 3248/4885MAPT 2499/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR NPC1 4782/4885RAB9A 4166/4885MAPT 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback